HC Wainwright & Co. Maintains Buy on BioCardia, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on BioCardia (NASDAQ:BCDA) but has lowered the price target from $9 to $4.

September 06, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioCardia's price target has been lowered from $9 to $4 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. indicates a potential decrease in the stock's value. However, the maintained 'Buy' rating suggests that the stock is still expected to perform well in the market, despite the lower price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100